title: Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery.
abstract: OBJECTIVE
  This study analyzed the expression of integrins alpha(v)beta3 and alpha(v)beta5 in glioma tissue and focused on the periphery of high-grade gliomas.
  
  
  METHODS
  The analysis was performed with Western blot, immunohistochemistry, and immunofluorescence, by use of two monoclonal antibodies able to recognize the functional integrin heterodimer. The expression of integrin-related ligands and growth factors also was studied. Sections from the tumor periphery were classified as either tumor periphery (light tumor infiltrate or scant visible cells) or peritumor (heavy tumor infiltration).
  
  
  RESULTS
  Our data on glioma tissues demonstrated that both integrins were expressed in glioma cells and vasculature and their expression correlated with the histological grade. Alpha(v)beta3 expression was prominent in astrocytic tumors. Both integrins were markers of tumor vasculature, particularly of endothelial proliferation. A high-grade glioma periphery demonstrated a prominent expression of integrin alpha(v)beta3. Cells demonstrating alpha(v)beta3 positivity were identified as tumor astrocytes and endothelial cells by double imaging. The same cells were surrounded by some alpha(v)beta3 ligands and co-localized fibroblast growth factor 2. Matrix metalloproteinase 2 also was found to be co-localized with alpha(v)beta3 in the same cells. Alpha(v)beta3 expression was more relevant in tumor astrocytes. Alpha(v)beta3 integrin and vascular endothelial growth factor expression increased from the periphery to the tumor center.
  
  
  CONCLUSIONS
  Our data support the role of integrins alpha(v)beta3 and alpha(v)beta5 in glioma-associated angiogenesis. In addition, they suggest a role for integrin alpha(v)beta3 in neoangiogenesis and cell migration in high-grade glioma periphery.
authors.affiliation: Institute of Neurosurgery, University of Milano, Ospedale Maggiore Policlinico, IRCCS, Italy. lbello@rics.bwh.harvard.edu
authors.forename: L
authors.initials: L
authors.lastname: Bello
authors.forename: M
authors.initials: M
authors.lastname: Francolini
authors.forename: P
authors.initials: P
authors.lastname: Marthyn
authors.forename: J
authors.initials: J
authors.lastname: Zhang
authors.forename: R S
authors.initials: RS
authors.lastname: Carroll
authors.forename: D C
authors.initials: DC
authors.lastname: Nikas
authors.forename: J F
authors.initials: JF
authors.lastname: Strasser
authors.forename: R
authors.initials: R
authors.lastname: Villani
authors.forename: D A
authors.initials: DA
authors.lastname: Cheresh
authors.forename: P M
authors.initials: PM
authors.lastname: Black
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D001808:Blood Vessels / Q000378:metabolism; D015153:Blotting, Western; D001932:Brain Neoplasms / Q000098:blood supply / Q000378:metabolism* / Q000473:pathology; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism; D005455:Fluorescent Antibody Technique; D005910:Glioma / Q000098:blood supply / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D016023:Integrins / Q000378:metabolism*; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D008875:Middle Aged; D019030:Receptors, Vitronectin / Q000378:metabolism*; D014018:Tissue Distribution; D014407:Tumor Cells, Cultured
chemical_list: D000911:Antibodies, Monoclonal; D016023:Integrins; D019030:Receptors, Vitronectin; C064660:integrin alphaVbeta5; D016222:Fibroblast Growth Factor 2; D020778:Matrix Metalloproteinase 2